Key clinical point: Deciding between newer second-line diabetes drug classes has a lot to do with whether the main concern is heart failure or cardiovascular events.
Major finding: Initiating an SGLT2 inhibitor versus a GLP-1 receptor agonist in the elderly was associated with a 34% decrease in the risk of heart failure hospitalizations, but there was a 25% increased risk of the composite primary outcome of myocardial infarction, stroke, and all-cause mortality among those without preexisting cardiovascular disease.
Study details: Review of Medicare claims data for almost 90,000 type 2 diabetes patients.
Disclosures: The work was funded by the National Institutes of Health. The lead investigator disclosed research funding from Boehringer Ingelheim and GlaxoSmithKline.
REPORTING FROM ADA 2019